

Table S3. A list of plasmids (A) and DNA oligos (B) used in this study.

Name	Parental plasmid	Characteristics and cloning site	Plasmid construction
FLAG-E6*E7 (pMA15)	p3XFLAGCMV14	HPV16 E6*E7, EcoRI/Asp718	Insert was amplified using a primer pair of oZM2411/oZM2431 from pTMF51
HA-E6*E7 (pMA48)	pSG5L-HA	HPV16 E6*E7, BamHI/XhoI	Insert was amplified using a primer pair of oMA130/oSB29 from pMA15
HA-HSP90β	pcDNA3	Human HSP90β, NotI	Purchased from addgene (#22487) (Garcia-Cardena et al., 1998)
Myc-GRP78	pcDNA3	Human GRP78, HindIII/XbaI	Purchased from addgene (#27164)
HPV16 E6E7 (pMA16)	pEGFP-N1	HPV16 nt 81-880, XhoI/Asp718	(Ajro et al., 2012)
GFP-E6 (pZM270)	pEGFP-C1	HPV16 nt 81-880, XhoI/Asp718	(Tao et al., 2003)
GFP-E671 (pZM271)	pEGFP-C1	HPV16 nt 81-227/408-559, XhoI/Asp718	(Tao et al., 2003)
GFP-E7 (pZM274)	pEGFP-C1	HPV16 nt 560-880, XhoI/Asp718	(Tao et al., 2003)
pMA51	pMA16	HPV16 nt 81-880 (A716G), XhoI/Asp718	Mutation was created by PCR by oZM2209/oMA162 and oMA163/oZM2262 from pMA16, following annealing and PCR by oZM2209/oZM2262
pMA52	pMA16	HPV16 nt 81-880 (A718G), XhoI/Asp718	Mutation was created by PCR by oZM2209/oMA164 and oMA165/oZM2262 from pMA16, following annealing and PCR by oZM2209/oZM2262
pMA53	pMA16	HPV16 nt 81-880 (A716G, A718G), XhoI/Asp718	Mutation was created by PCR by oZM2209/oMA166 and oMA167/oZM2262 from pMA16, following PCR by oZM2209/oZM2262
pMA54	pMA16	HPV16 nt 81-880 (A716G, A718G, A719G, A721G), XhoI/Asp718	PCR fragments by oZM2209/oMA168 and oMA169/oZM2262 from pMA16 were annealed and followed by PCR by oZM2209/oZM2262
pMA58	pMA16	HPV16 nt 81-350/680-885, XhoI/NotI	PCR fragments by oZM212/oMA217 and oMA215/oZM2262 from pMA16 were annealed and followed by PCR by oZM2217/oZM2262
pMA59	pMA58	HPV16 nt 81-350/680-885(A716G), XhoI/NotI	PCR fragments by oZM212/oMA217 and oMA215/oZM2262 from pMA51 were annealed and followed by PCR by oZM2217/oZM2262
pMA60	pMA58	HPV16 nt 81-350/680-885(A718G), XhoI/NotI	PCR fragments by oZM212/oMA217 and oMA215/oZM2262 from pMA52 were annealed and followed by PCR by oZM2217/oZM2262
pMA61	pMA58	HPV16 nt 81-350/680-885(A716G, A718G), XhoI/NotI	PCR fragments by oZM212/oMA217 and oMA215/oZM2262 from pMA53 were annealed and followed by PCR by oZM2217/oZM2262
pMA63	pMA58	HPV16 nt 81-350/680-885+β-globin nt 146-484, XhoI/NotI	PCR fragments by oZM2262/oMA238 from pMA58 and oMA239/oZM2240 from human β-globin plasmid were annealed and followed by PCR by oZM2262/oZM2240
pMA65	pMA59	HPV16 nt 81-350/680-885(A716G)+β-globin nt 146-484, XhoI/NotI	PCR fragments by oZM2262/oMA238 from pMA58 and oMA239/oZM2240 from human β-globin plasmid were annealed and followed by PCR by oZM2262/oZM2240
pMA66	pMA60	HPV16 nt 81-350/680-885(A718G)+β-globin nt 146-484, XhoI/NotI	PCR fragments by oZM2262/oMA238 from pMA58 and oMA239/oZM2240 from human β-globin plasmid were annealed and followed by PCR by oZM2262/oZM2240
pMA67	pMA61	HPV16 nt 81-350/680-885(A716G, A718G)+β-globin nt 146-484, XhoI/NotI	PCR fragments by oZM2262/oMA238 from pMA58 and oMA239/oZM2240 from human β-globin plasmid were annealed and followed by PCR by oZM2262/oZM2240

Name (alternative name)	Position	Restriction enzyme site	Sequence (5' to 3')
oMA31 (R4)	HPV16, nt 267-245		CTATATACTATGCATAAATCCCG
oMA130A	HPV16, nt 104-121	BamHI	CATGGATCCGCCACC/ATGTTTCAGGACCCACAG
oMA162	HPV16, nt 711-735		CCATT@CAATATTGTAACCTTTTGT
oMA163	HPV16, nt 729-695		GGTTACAATATTGGAATGGGCTCTGTCGGGTTCTG
oMA164	HPV16, nt 711-737		CCATTACGATATTGTAACCTTTTGTG
oMA165	HPV16, nt 729-695		GGTTACAATATTGGAATGGGCTCTGTCGGGTTCTG
oMA166	HPV16, nt 711-737		CCATT@CGATATTGTAACCTTTTGTG
oMA167	HPV16, nt 729-695		GGTTACAATATTGGAATGGGCTCTGTCGGGTTCTG
oMA168	HPV16, nt 711-745		CCATT@CGGTTGTTGTAACCTTTTGTGCAAGTGTG
oMA169	HPV16, nt 729-695		GGTTACAACACCGGAATGGGCTCTGTCGGGTTCTG
oMA222	HPV16, nt 217-186 (6-FAM+TAMRA)		CAGTAACTGTTGCTTGCAGTACACACATTCTA
oMA213	HPV16, nt 245-220		GAAAAGCAAAGTCATATACCTCACGT
oMA214	HPV16, nt 541-526/226-220		ACGTGTTCTTGATGATCTCACGT
oMA215	HPV16, nt 691-680/350-333		GTCCAGCTGGAC/AACTATAACAATAATGTC
oMA216	HPV16, nt 755-742/226-220		AGCGTAGAGTCAC/CTCACGT
oMA217	HPV16, nt 885-868	Not I	CTAG@GGCCGG/GGTACTGCAGGATCAGC
oMA233	HPV16, nt 428-409/226-220		GCTTTTGCAGTAAATACACCTCACGT
oMA238	Human β-globin nt 146-165/HPV16 nt 871-880		ATCCCTGCAG/GTTGGATCAAGGTTACAAG
oMA239	Human β-globin nt 153-146/HPV16 nt 880-871		ATACCAA@CTGCAGGATCAGCCATGG
oMA241	HPV18, nt 804-791/233-227		ATTCTGGCTTCA@CTCTGTA
oSB29	HPV16, nt 858-840	Xho I	AGTCG@TCGAG/TTATGGTTTCTGAGAACAG
oSB56	HPV16, nt 525-504		CTGCA@CAAGACATACATCGAC
oZM2209	HPV16, nt 902-885		GTACCCTCTTCC@CATG
oZM2211	HPV16, nt 718-701		TGTAA@GGCTCTGCTCCG
oZM2212	HPV16, nt 625-608		GATCAGTGTCTCTG@TTGTC
oZM2217	HPV16, nt 429-409+U1 binding site		GTACTCACCC@GGCTTTTGACAGTAAATACAC
oZM2220	HPV16, nt 540-522		CSTGTTCTTGATG@TCTGC
oZM2237 (F3)	HPV16, nt 108-125		GTTTCAGGACCC@CAGGAGC
oZM2240	CMV IE promoter		GACTTTC@ACTTGGCAG
oZM2252	HPV18, nt 121-140		ATCC@ACACGGCAGCCCTAC
oZM2262	HPV16, nt 81-99	Xho I	ATTCG@CTCAGG/TTATGCACAAAGAGAAC
oZM2264 (R3)	HPV16, nt 289-272		TACAG@ATATGGATTCCC
oZM2269	Human GAPDH nt 202-225		GTCA@CAATGGAATCCCATCACC
oZM2270	Human GAPDH nt 523-502		TGAGTCC@TTCACGATACCAAA
oZM2296	pEGFP-C1 plasmid nt 880-862		GCATGG@CGGACTTGAAGAA
oZM2301 (F2)	HPV16, nt 562-581		CACC@ATGCATGGAGATACACCTAC
oZM2302 (R1)	HPV16, nt 855-836		TGTTTTCTG@AGACAGATGG
oZM2359	HPV16, nt 762-742/226-221		CAACCGA@GCGTAGAGTCACTCACG
oZM2380	HPV16, nt 791-773		CGAATG@TCACTGTGTGTC
oZM2381 (F1)	HPV16, nt 205-223		GCAACAGT@TCTGCGACGT
oZM2411	HPV16, nt 104-121	EcoRI	ATCGGA@TTCACCA/ATGTTTCAGGACCCACAG
oZM2413	HPV16, nt 211-226/409-411		GTTACTG@GACGTGAG/GTG
oZM2414	HPV16, nt 211-226/526-528		GTTACTG@GACGTGAG/ATC
oZM2417 (R2)	HPV16, nt 374-356		GCTGTT@TAATGTTGTTCC
oZM2431	HPV16, nt 854-835	Asp718	CACTGAGG@TACC/GGTTTCTGAGA@ACAGATGGG

* mutated nucleotide(s) and restriction enzyme cutting sites are underlined.